TW200833842A - Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents - Google Patents

Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents

Info

Publication number
TW200833842A
TW200833842A TW096148197A TW96148197A TW200833842A TW 200833842 A TW200833842 A TW 200833842A TW 096148197 A TW096148197 A TW 096148197A TW 96148197 A TW96148197 A TW 96148197A TW 200833842 A TW200833842 A TW 200833842A
Authority
TW
Taiwan
Prior art keywords
glaucoma
treatment
serum amyloid
diagnosis
gene
Prior art date
Application number
TW096148197A
Other languages
English (en)
Inventor
Abbot F Clark
Wan-Heng Wang
Loretta Graves Mcnatt
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of TW200833842A publication Critical patent/TW200833842A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
TW096148197A 2006-12-22 2007-12-17 Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents TW200833842A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/615,454 US7662389B2 (en) 2003-12-17 2006-12-22 Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents

Publications (1)

Publication Number Publication Date
TW200833842A true TW200833842A (en) 2008-08-16

Family

ID=39205179

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096148197A TW200833842A (en) 2006-12-22 2007-12-17 Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents

Country Status (18)

Country Link
US (2) US7662389B2 (zh)
EP (2) EP2428210B1 (zh)
JP (1) JP2010513563A (zh)
KR (1) KR20090101889A (zh)
CN (1) CN101563081A (zh)
AR (1) AR064499A1 (zh)
AU (1) AU2007337059A1 (zh)
BR (1) BRPI0720847A2 (zh)
CA (1) CA2669916A1 (zh)
CL (1) CL2007003800A1 (zh)
ES (1) ES2424123T3 (zh)
MX (1) MX2009004402A (zh)
RU (2) RU2461378C2 (zh)
SA (1) SA07280713B1 (zh)
TW (1) TW200833842A (zh)
UY (1) UY30837A1 (zh)
WO (1) WO2008079783A1 (zh)
ZA (1) ZA200902454B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
CN101921799B (zh) * 2010-01-18 2014-02-26 德赛诊断系统(上海)有限公司 马血清淀粉样蛋白a1制备方法及表达载体和基因工程菌
US10175251B2 (en) * 2010-04-13 2019-01-08 M-Lab Gmbh Diagnostic methods for glaucoma
CN103160575B (zh) * 2011-12-15 2014-10-01 王荣芳 SAA1β/β纯合子基因型在肝硬化预后诊断及肝硬化诊断中的应用
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
LT2855500T (lt) * 2012-05-24 2020-11-10 Ionis Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti apolipoproteino (a) raiškos moduliacijai
US10813920B2 (en) 2013-11-14 2020-10-27 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
CA3008113A1 (en) 2015-12-24 2017-06-29 The Doshisha Drug for treating or preventing disorder caused by tgf-.beta. signals, and application thereof
MY202289A (en) * 2017-04-04 2024-04-22 Kinarus Ag Methods of preventing or treating ophthalmic diseases
CN112410419A (zh) * 2020-12-17 2021-02-26 德赛诊断系统(上海)有限公司 基于淬灭探针的血清淀粉样蛋白a1基因型的检测方法和试剂盒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
WO2001001986A1 (en) 1999-07-02 2001-01-11 Lipton Stuart A Method of reducing neuronal injury or apoptosis
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
TWI398261B (zh) 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents

Also Published As

Publication number Publication date
ES2424123T3 (es) 2013-09-27
SA07280713B1 (ar) 2012-01-24
UY30837A1 (es) 2008-07-03
AU2007337059A1 (en) 2008-07-03
CA2669916A1 (en) 2008-07-03
EP2428210A1 (en) 2012-03-14
EP2120926A1 (en) 2009-11-25
EP2428210B1 (en) 2013-07-10
CN101563081A (zh) 2009-10-21
JP2010513563A (ja) 2010-04-30
CL2007003800A1 (es) 2008-08-22
MX2009004402A (es) 2009-05-11
KR20090101889A (ko) 2009-09-29
RU2461378C2 (ru) 2012-09-20
RU2012123516A (ru) 2013-12-20
US20100063052A1 (en) 2010-03-11
US20070208043A1 (en) 2007-09-06
US7662389B2 (en) 2010-02-16
AR064499A1 (es) 2009-04-08
RU2009128245A (ru) 2011-01-27
BRPI0720847A2 (pt) 2014-03-04
ZA200902454B (en) 2010-07-28
WO2008079783A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
TW200833842A (en) Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
WO2008079326A3 (en) Methods for using and identifying modulators of delta-like 4
MX2009009207A (es) Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
WO2005060542A3 (en) Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
TW200714283A (en) Method and composition for treating peripheral vascular diseases
EP2061907A4 (en) TCL1 EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA (LLC) REGULATED BY MIR-29 AND MIR-181
MX346450B (es) Composiciones y métodos para el tratamiento de la enfermedad celíaca.
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
TW200716141A (en) Compositions and methods for treatment for neoplasms
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
MX2009009738A (es) Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento.
WO2010059242A3 (en) Neurodegenerative disease diagnostic compositions and methods of use
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
MY162136A (en) Activin-actrii antagonists and uses for treating anemia
BRPI0518289A2 (pt) mÉtodos e composiÇÕes para o tratamento de desordens oculares
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
WO2007098047A3 (en) Methods and compositions for the treatment of parkinson's disease